Katy Beckermann, MD, PhD
Kathryn Beckermann, MD, PhD, is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt University Medical Center. She is a GU medical oncologist specialized in treating kidney, bladder, prostate, and testicular cancer.
Articles by Katy Beckermann, MD, PhD
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
Drs. Beckermann and Hutson compare the QOL data for tivozanib and belzutifan in patients with relapsed or refractory aRCC.
Drs. Hutson and Beckermann summarize the long-term TIVO-3 data for patients with relapsed or refractory advanced RCC.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
Dr. Beckermann shares why there is a need to identify a biomarker for patients with RCC who will benefit from belzutifan.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.